Aurobindo Pharma subsidiary launches generic of cancer drug

Aurobindo Pharma subsidiary Eugia Pharma Specialities has launched Pomalidomide Capsules, successful antithetic strengths, successful the U.S. market.

Eugia was 1 of the first-to-file (FTF) ANDA applicants for the merchandise and volition manufacture the product, which is utilized to dainty relapsed oregon refractory aggregate myeloma and AIDS-related Kaposi sarcoma, astatine its Unit-I.

The merchandise is simply a generic equivalent of BMS Pharmaceuticals Corp’s Pomalyst Capsules. In the U.S. for the 12 months ending January 2026, Pomalidomide capsules had an estimated marketplace size of astir $ 3.3 billion, Aurobindo Pharma said citing IQVIA MAT data.